4TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION MEETING

THE ROCKY ROAD TO VIRAL HEPATITIS ELIMINATION: ASSURING ACCESS TO ANTIVIRAL THERAPY FOR ALL CO-INFECTED PATIENTS FROM LOW TO HIGH INCOME SETTINGS

22 - 23 JULY 2017

Amphithéâtre Farabeuf, Campus des Cordeliers, Université Pierre et Marie Curie (UPMC)

21 rue de l’Ecole de Médecine, Paris, France
MEETING OVERVIEW

The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and takes place prior to the 9th IAS Conference on HIV Science (IAS 2017) at the Campus des Cordeliers, Université Pierre et Marie Curie (UPMC) in Paris, France.

Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting provides a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting also takes advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It is also an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.

The meeting focuses on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting has a particular focus on access to care and new curative treatments especially for vulnerable populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics are explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.
## PROGRAMME

### SATURDAY 22 JULY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:30</td>
<td>Registration and welcome coffee</td>
</tr>
<tr>
<td>08:30 – 08:40</td>
<td>Meeting opening                                                         Marina Klein</td>
</tr>
<tr>
<td>08:40 – 09:00</td>
<td>Welcome to France: Update on the role of community research for hepatitis prevention Patrizia Carrieri</td>
</tr>
<tr>
<td>09:00 – 09:25</td>
<td>Update on global epidemiology/elimination targets: Are we on track? Gottfried Hirnschall</td>
</tr>
<tr>
<td>09:25 – 10:15</td>
<td>Emerging epidemics: Will they derail progress?</td>
</tr>
<tr>
<td></td>
<td>• Eastern/Central Europe                                               Marieta Simonova</td>
</tr>
<tr>
<td></td>
<td>• Rural HIV-HCV related epidemics in the USA                             John T. Brooks</td>
</tr>
<tr>
<td>10:15 – 10:40</td>
<td>Where are we now on priorities identified at Durban? Monique Andersson</td>
</tr>
<tr>
<td>10:40 – 10:50</td>
<td>Discussion                                                              All speakers</td>
</tr>
<tr>
<td>10:50 – 11:15</td>
<td>Break &amp; poster viewing</td>
</tr>
</tbody>
</table>

### Taking stock | Session co-chairs: Linda-Gail Bekker and Oluwaseun Falade-Nwulia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 13:45</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>12:30 - 13:10</td>
<td>HBV                                                                     Jordan Feld</td>
</tr>
<tr>
<td>13:10 - 13:45</td>
<td>Immunology                                                               Niklas Luhmann</td>
</tr>
<tr>
<td></td>
<td>Diagnostics                                                             Slim Fourati</td>
</tr>
<tr>
<td></td>
<td>Linkage to care                                                         All speakers</td>
</tr>
</tbody>
</table>

### Diagnostics | Session co-chairs: Anne Loarec and Amare Eshetu

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 11:35</td>
<td>New diagnostics: Point of care testing for HCV Jordan Feld</td>
</tr>
<tr>
<td>11:35 – 11:55</td>
<td>The evolution in HBV markers Slim Fourati</td>
</tr>
<tr>
<td>11:55 – 12:15</td>
<td>Approaches for simplified diagnostic/screening algorithms Niklas Luhmann</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>Discussion                                                              All speakers</td>
</tr>
<tr>
<td>12:30 – 13:45</td>
<td>Lunch &amp; poster viewing</td>
</tr>
</tbody>
</table>

*Update on global epidemiology/elimination targets: Are we on track?*

*Emerging epidemics: Will they derail progress?*

*Where are we now on priorities identified at Durban?*

*Discussion*
## Linkage to care: Different strokes for different folks?
Session co-chairs: Sergii Dovriak and Nadine Kronfli

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45 – 14:00</td>
<td>People who inject drugs</td>
<td>Margaret Hellard</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Prisoners</td>
<td>Rick Altice</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Men who have sex with men</td>
<td>Andri Rauch</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>Community-driven programmes</td>
<td>Anton Basenko</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Discussion</td>
<td>All speakers</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Break &amp; poster viewing</td>
<td></td>
</tr>
</tbody>
</table>

## Treatment | Session co-chairs: Mauro Schechter and Christoph Boesecke

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 – 15:40</td>
<td>Treatment guidelines update</td>
<td>Alessio Aghemo</td>
</tr>
<tr>
<td>15:40 – 16:05</td>
<td>Shorter durations and pan-genotypic regimens: The final frontier?</td>
<td>Greg Dore</td>
</tr>
<tr>
<td>16:05 – 16:30</td>
<td>HCV treatment in active PWID: Is there a concern about reinfection?</td>
<td>Jason Grebely</td>
</tr>
<tr>
<td>16:30 – 16:55</td>
<td>What do clinicians need to watch for with DAA therapy?</td>
<td>Jürgen Rockstroh</td>
</tr>
<tr>
<td>16:55 – 17:25</td>
<td>Case discussions (difficult management issues in HCV/HBV)</td>
<td>Sanjay Bhagani</td>
</tr>
<tr>
<td></td>
<td>• Case discussion 1</td>
<td>Lionel Piroth</td>
</tr>
<tr>
<td></td>
<td>• Case discussion 2</td>
<td></td>
</tr>
<tr>
<td>17:25 – 17:30</td>
<td>Discussion</td>
<td>All speakers</td>
</tr>
<tr>
<td>17:30 – 20:00</td>
<td>Reception &amp; poster viewing</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment Scale-up

- 17:30 - 18:10 – Treatment
- 18:10 - 18:50 – Outcomes and co-morbidities
SUNDAY 23 JULY

08:00 – 08:30 Welcome coffee

Bringing it together: The scale up | Session co-chairs: Kenneth Ngure and Linda Wittkop

08:30 – 08:50 Is elimination possible and what will it take to achieve it? Natasha Martin

08:50 – 09:10 Test and treat: Dutch MSM treatment experience Bart J.A. Rijnders

09:10 – 09:30 Economics and sustainability: The role of generics Andrew Hill

09:30 – 09:50 Access in high income countries: The European landscape Jeffrey Lazarus

09:50 – 10:10 Community experience with expanded access Pascal Mélin

10:10 – 10:15 Discussion All speakers

Looking to the future | Session co-chairs: Adeeba Kamarulzaman and Jacques Normand

10:15 – 10:35 Research gaps in viral hepatitis Jean-Michel Pawlotsky

10:35 – 10:55 HAV outbreak in Europe Anne-Marie Rique-Afonso

10:55 – 11:00 Discussion All Speakers

11:00 – 11:15 Break & poster viewing

Panel discussion: Priorities for enhancing access and how to achieve them | Session chair: Tracy Swan

11:15 – 11:30 Global state of HCV treatment access Tracy Swan

11:30 – 12:30 Panel discussion (Roundtable and audience participation) Isabelle Andrieux-Meyer, Anton Basenko, James Freeman, Céline Grillon, Othoman Mellouk, Luís Mendão

Closing

12:30 – 12:45 Meeting summary Karine Lacombe

12:45 – 13:00 Moving forward to address HIV co-infections and co-morbidities Anton Pozniak
POSTER ABSTRACTS

EPIDEMIOLOGY

1. Assessment of prevalence of HIV, hepatitis C, HIV/hepatitis C co-infection and risk behaviours among female injecting drug users in Nepal
J. Damas, K. Deuba, U. Shrestha, B. Rawal, T. Paudel, G. Marrone

2. Burden of infectious diseases and substance abuse among incarcerated women in Kuala Lumpur, Malaysia
V. Pillai, C. Pedersen, J. Wickersham, F. Altice, A. Kamarulzaman

3. Chronic hepatitis C and HIV co-infection among people who inject drugs along the Kenyan Coast

4. Countrywide epidemiology of B, C and Delta hepatitis in Burkina Faso: The ANRS 12270 clustered cross-sectional study

5. Crystal methamphetamine initiation among HIV-positive and HIV-negative men who have sex with men in Vancouver, Canada: A longitudinal analysis

6. HCV genotype profile in Brazil among HIV infected and uninfected individuals: A survey truly representative of an entire country

7. Hepatitis E virus serological and molecular testing in 1979 patients followed-up in 2014-2016 in HIV reference centers of university hospitals of Marseille, southeastern France

8. Predictors and incidence of sexually transmitted hepatitis C virus infection in HIV positive men who have sex with men

9. Predictors of HCV seroconversion in people who inject drugs in 5 regions of Ukraine
A. Meteliuk, A. Mazhnaya, S. Filippovych, F.L. Altice

C.A. Semá Baltazar, M. Boothe, I. Sathane, E. Fazito, R. Horth, N. Bhatt

11. Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: A systematic review and meta-analysis

13. Circulating mucosal associated invariant T cells (MAITs) fail to be recovered by successful direct-acting antiviral therapy (DAA) in HIV/HCV co-infected patients

14. Untreated HCV-coinfection in HIV-infected patients induces additional CD4+ T-lymphocyte deficiency due to mobilization of naive cells into immune response resulting in their regeneration failure
K. Shmagel, E. Saidakova, L. Korolevskaia, N. Shmagel, V. Chereshnev

15. Chronic hepatitis C among intravenous drug users in Tanzania: Assessment of the liver disease and utility of HCV core antigen detection and quantification

16. Comparison of two immunoassays for simultaneous detection of HCV antigen and antibodies among HCV/HIV co-infected patients in dried serum spots

17. Usual APRI score thresholds lack sensitivity to prioritize for hepatitis C treatment in a HCV/HIV coinfected cohort in Cambodia
A. de Weggheleire, S. An, J. Buyze, S. Thai, S. Francque, L. Lynen

18. Validation and scale-up of hepatitis B viral load on polyvalent open PCR platforms in West African and South East Asian countries. A study of the AC12 working group (ANRS 12327)

19. Hepatitis C care cascade for people living with HIV in the country of Georgia
N. Chkhartishvili, A. Abutidze, N. Bolokadze, O. Chokoshvili, N. Dvali, L. Sharvadze, T. Tsertsadze

20. Integrated Surveillance for HIV, syphilis, HBV & HCV in pregnant women attending ANC sentinel surveillance sites in Eritrea, 2016
A.B. Mesfin, H. Ahmed, M. Asrat, T. Asfaha, N. Tesfamichael

21. Alanine aminotransferase level monitoring to detection hepatitis B virus reactivation in 170 HIV/hepatitis C virus-infected patients on direct-acting agent-based therapies

22. Association of uncontrolled HIV-RNA with failure to direct acting antiviral (DAA) combinations in HIV/HCV co-infected patients on antiretroviral therapy (ART) - ANRS CO13 HEPAVIH cohort
23. Chronic hepatitis C in human immunodeficiency virus infected patients: Real-life treatment with new generation direct-acting antivirals in a Portuguese centre
A. Silva-Pinto, R. Ruas, I. Abreu, F. Ceia, A.C. Carvalho, N. Neves, A.S. Santos, J. Soares, C. Piñeiro, R. Serrão, A. Sarmento

24. Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: The EXPEDITION-2 study

25. Evolution of glomerular filtration rate in patients concomitantly treated with ledipasvir and tenofovir

26. HCV cure for HIV-infected patients: Not so easy to achieve in routine practice

27. Role of PLHIV networks in facilitating hepatitis C cascade of care in South and South East Asia
O. Syarif

28. The road to elimination of hepatitis C: Analysis of SVR versus new HCV infections in 91 countries
A. Hill, S. Nath, B. Simmons

29. The Global Accelerator for Paediatric Formulations (GAP-f): Ensuring children have accelerated access to optimal drug formulations
S. Morin, M. Vicari, M. Watkins, L. Lewis, F. Pascual, P. Easterbrook, M. Penazzato, GAP-f partners

OUTCOMES AND CO-MORBIDITIES

M.E. Santos, R. Abrahão Ribeiro, A. Stevens, M.P. Carrieri, W. Navegantes de Araújo

31. Coffee intake modifies the relationship between alcohol consumption and liver fibrosis in patients co-infected with HIV and hepatitis C virus (ANRS CO13-HEPAVIH cohort)

32. Comparative steatosis rates by liver biopsy and transient elastography controlled attenuated parameter (CAP) in hepatitis C (HCV) and HIV/HCV coinfection in a large U.S. hepatitis clinic: Time to take notice
J. Martin, O. Adeyemi, K. Burke, I. Alvaraz, C. Winston, S. Markham, B. Go, G. Huhn

33. Daily cannabis use and reduced risk of severe steatosis in a population of patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH)
S.E. Nordmann, A. Vilotitch, P. Roux, L. Esterle, B. Spire, F. Marcellin, D. Salmon-Ceron, F. Dabis, J. Chas, D. Rey, L. Wittkop, P. Sogni, P. Carrieri, ANRS CO13 HEPAVIH study group

34. Does the non-alcoholic fatty liver disease (NAFLD) score predict liver fibrosis progression after hepatitis C virus (HCV) treatment in human immunodeficiency virus (HIV)-HCV co-infected patients?
N. Kronfli, R. Nitulescu, S. Walmsley, C. Cooper, S. Haider, J. Gill, M.-L. Vachon, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators
35. Effects of long-term ART on total HIV DNA levels in Japanese patients with and without haemophilia+HCV

36. Increased risk of overweightness and obesity after HCV clearance in patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH cohort)

37. Occult liver cirrhosis diagnosed by transient elastography is frequent and under-monitored in HIV-infected patients: Results of a large-scale screening program
A. Benmassaoud, T. Pembroke, B. Lebouche, P. Ghali, M. Deschenes, M. Klein, G. Sebastiani

38. Sustained virologic response (SVR) after hepatitis C virus (HCV) treatment does not lead to improved renal function in HIV/HCV coinfected patients
C. Rossi, E. Moodie, M. Hull, V. Martel-Lafferriere, M.-L. Vachon, C. Cooper, N. Pick, S. Walmsley, M. Klein, Canadian Coinfection Cohort

39. An economic evaluation of the integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis
L. Zhang, L. Ferradini, N. Ishikawa, J.V. Woodring, Y. Tao, M. Nagai, Y.-R. Lo

40. Eliminating HCV/HIV coinfection through enhanced treatment: HCV treatment in primary care is feasible and highly effective

41. Expanding the provider base: HIV and hepatitis C clinical preceptorships in New York State
N. Harris, T. Wilder, J. Steinke, R. Walsh, A. Urbina

42. Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient
A. Hill, M. Barber, D. Gotham, J. Fortunak, A. Pozniak

43. Georgia’s path towards HCV elimination
L. Sulaberidze, I. Chikovani, M. Uchaneishvili, N. Shengelia

HBV

44. HBV co-infection is associated with high one-year mortality in HIV-infected Tanzanians on ART
Christian, E. Fabian, L.R. Ammerman, I. Macha, C. Gawile, S. Mpangala, N. Ulenga, C. Thio, R. Murphy, C. Hawkins

45. Hepatitis B virus infection in HIV-1 negative and positive pregnant women in Botswana, implications for HBV vertical transmission

46. Preliminary results of prevention of mother-to-child transmission of hepatitis B virus through treatment of mothers and vaccination of newborns at Ouagadougou, Burkina Faso
A.N. Guingane, N. Meda, R. Sombié, I. Guiraud, A. Bougouma
4TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION MEETING

THE ROCKY ROAD TO VIRAL HEPATITIS ELIMINATION: ASSURING ACCESS TO ANTIVIRAL THERAPY FOR ALL CO-INFECTED PATIENTS FROM LOW TO HIGH INCOME SETTINGS

CO-CHAIRS

MARINA KLEIN
McGill University
CIHR Canadian HIV Trials Network
Montreal, Canada

KARINE LACOMBE
Hôpital Saint-Antoine
Paris, France

ORGANIZING COMMITTEE MEMBERS

MONIQUE ANDERSSON
Stellenbosch University, Faculty of Health Science
Cape Town, South Africa

GAIL MATTHEWS
Kirby Institute
Sydney, Australia

ISABELLE ANDRIEUX-MEYER
Drugs for Neglected Diseases initiative
Geneva, Switzerland

SÉBASTIEN MORIN
International AIDS Society
Geneva, Switzerland

SANJAY BHAGANI
Royal Free Hospital
London, UK

JACQUES NORMAND
National Institute on Drug Abuse
Washington D.C., USA

CHRISTOPH BOESECKE
University of Bonn
Bonn, Germany

JEAN-MICHEL PAWLOTSKY
Henri Mondor University Hospital
Crêteil, France

LAURENT CASTERA
Hôpital Beaujon
Paris, France

MARION PETERS
University of California
San Francisco, USA

GREG DORE
Kirby Institute
Sydney, Australia

LIONEL PIROTH
CHU Dijon Bourgogne
Dijon, France

JORDAN FELD
University of Toronto
Toronto, Canada

JÜRGEN ROCKSTROH
University of Bonn
Bonn, Germany

NIKLAS LUHMANN
Médecins du Monde
Paris, France

TRACY SWAN
Freelancer
New York, USA

LUDMILA MAISTAT
Alliance for Public Health
Kiev, Ukraine